With 3 sell/buy ratio, Teva Pharmaceutical Industries Limited (NYSE:TEVA) experienced more insider selling than insider buying over the last three months. Could this be a sign for outside investors to start selling as well? TEVA recorded 3 sales on the open market in the last three months. They sold nearly 2,922 shares while purchases amounted to zero shares that period. Looking even further back to 12 months, corporate insiders offloaded 42,113 shares when buyers snapped up 752,000 shares. The 12-month’s totals signify about a 0.06-to-1 sell/buy ratio.
Fridriksdottir Hafrun parted with a total of 1.64 thousand shares of Teva Pharmaceutical Industries Limited (TEVA) at average share price of $15.7. This insider trade in the company took place on 01/02/2019. The total for the sales was set at $25.8 thousand. After this transaction, the Executive VP, Global R&D account balance stood at 11.83 thousand shares. The stock grew 17.52 percent since that insider sale. On 11/30/2018, Fridriksdottir Hafrun, Executive VP, Global R&D, sold 0.93 thousand shares at a price per share of $21.76. This removed 20.3 thousand shares from the insider’s fortune and the stock saw a -15.21 percent retreat in value since the news became public. This transaction left 8.83 thousand shares in the Executive VP, Global R&D account.
On 11/05/2018, EVP, CFO Mcclellan Michael James performed a sale transaction worth $7.86 thousand. This sale at $22.73 each has eliminated 0.35 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded -18.83 percent decrease since the transaction was reported. The insider now is left with 11.64 thousand shares remaining in the account. Daniell Richard, who performs the Exec. VP, European Commercial job, sold 2.49 thousand shares for $58.94 thousand. The disposal occurred on 09/18/2018 was priced at $23.69 per share. The share price plunged -22.12 percent since the reporting date. Daniell Richard now left with a stake of 0 thousand TEVA stock worth $0 thousand after the insider selling.
The 12-month median price target for Teva Pharmaceutical Industries Limited (TEVA) assigned by the analysts stands at $24, which represents a return potential of 30.08 percent when compared to the closing price of the stock of $18.45 on Friday, January 11. The lowest price target for the stock is $15 — slightly more than -18.7 percent from TEVA’s current share price. The stock will probably climb 23.09 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $30-month high price target. This represents a whopping 62.6 percent increase from where shares are trading today.
On momentum oscillators front, ‘RSI’ has touched 53.72 on daily chart, which may remain a cause for concern. If the price breaks below $17.97 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $18.61 mark may result into a pull-back move towards $18.77 level. The stock is currently hovering around the first support level of $18.21. Below this, the next support is placed in the zone of $17.97. Till the time, the TEVA stock trades above this level, bulls have nothing to fear.
Shares of Teva Pharmaceutical Industries Limited (TEVA) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry TEVA operates in has an average P/E of 31.12. Its P/E ratio went as low as 16.15X and as high as 512.3 over the 5-year span. Further, it is sporting a 0.99 on the Price-to-Sales ratio. Compare this with the industry average P/S of 4. 45.4 percent is the gross profit margin for Teva Pharmaceutical Industries Limited and operating margin sits at -59 percent. Along with this, the net profit margin is -56 percent.
On 11th of January, Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares ended higher after a volatile session. The shares accumulated 0.28 points or 1.54 percent at $18.45 with a light trade volume of 8.562 million shares. After opening the session at $18.21, the shares went as high as $18.53 and as low as $18.1301, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $19.5 billion and now has 1.06 billion shares outstanding. Teva Pharmaceutical Industries Limited (TEVA) stock has lost -0.32 percent of market value in 21 trading days.
In last reported earnings results, TEVA earned $0.68 per share, better than the $0.54, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $4.53B, in line with the $4.53B analysts expected. Earnings are estimated to increase by -26.9 percent this year, -3.51 percent next year and continue to increase by -7.33 percent annually for the next 5 years. Investors will get their next glimpse of TEVA’s Q4 earnings on February 07. Analysts are forecasting revenue to suffer decline of -17 percent to $4.53B in the next fiscal quarter, while earnings are seen soaring by nearly -41.94 percent to $0.54 per share. History has shown that shares in Teva Pharmaceutical Industries Limited have gone down on 18 different earnings reaction days and are predicted to add 0.05 percent when the company reports upcoming earnings.
TEVA stock has a trailing 3-year beta of 1.3, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$11.93 a share in the trailing twelve months. The stock’s value has surged 19.65 percent year to date (YTD) against a decline of -7.93 percent in 12 month’s time. The company’s shares still trade -28.93 percent away from its 1-year high of $25.96 and 26.46 percent up from 52-week low of $14.59. The average consensus rating on the company is 2.8, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.